The biotechnology company Seagen Inc. (SGEN) announced on Tuesday that its stockholders have approved a proposal under which Pfizer will acquire Seagen.
Under the merger agreement, Pfizer will acquire Seagen for $229 per share in cash for a total of $43 billion.
Seagen will file the final, certified voting results in Form 8-K with the SEC. The acquisition is expected to close in late 2023 or early 2024.
Tuesday, the stock closed at $194.01 in regular trading hours, up 0.27% or $0.52 a share, on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.